Bio-Rad to Host Droplet Digital PCR Webinar on Tuesday, August 26, 2025

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a renowned leader in life science research and clinical diagnostics, has announced an upcoming informational webinar focused on its innovative Droplet Digital™ PCR (ddPCR™) product portfolio. This event is set for Tuesday, August 26, 2025, at 10:00 AM Pacific Time (1:00 PM Eastern Time), and will be led by Bio-Rad’s President and COO, Jon DiVincenzo, alongside Chief Financial Officer, Roop K. Lakkaraju.

The webinar will cover a comprehensive presentation about the ddPCR technology, which is pivotal in enabling precise and sensitive nucleic acid quantification. Attendees will have the opportunity to engage in a Q&A session, allowing for a deeper understanding of the product's applications and benefits. Individuals interested in participating may join by dialing (800) 715-9871 in the U.S. or (+1) (646) 307-1963 internationally, using the access code 9562470. For those who prefer, a live webcast of the event will also be available on Bio-Rad’s "Investor Relations" website, along with the presentation slides. A replay of the webcast will remain accessible for up to a year post-event.

Bio-Rad, based in Hercules, California, boasts a robust presence in the life sciences and diagnostics sectors, employing around 7,500 people and generating $2.6 billion in revenue in 2024. Its diverse clientele ranges from universities and research institutions to biopharmaceutical companies and clinical laboratories. Committed to advancing scientific research and improving health outcomes, Bio-Rad continues to innovate across their product lines. For more information, visit their official website at bio-rad.com.

For further inquiries or media contact, please reach out to Edward Chung (Investor Relations) at 510-741-6104 or Anna Gralinska (Corporate Communications) at 510-741-6643.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) has positioned itself as a formidable entity in the life science research and clinical diagnostics sectors. Scheduled for August 26, 2025, the company will host a webinar highlighting its Droplet Digital™ PCR (ddPCR™) product portfolio, an imperative move for investors keen on understanding the potential growth drivers within the life sciences market.

Bio-Rad's ddPCR technology represents a significant advancement in precision for nucleic acid quantification, which is critical for various applications in research and clinical diagnostics. The upcoming webinar, hosted by key executives Jon DiVincenzo and Roop K. Lakkaraju, will offer insights into not only product innovations but also the strategic vision steering the company’s future. This engagement is particularly important given the increasing demand for precise genetic analysis tools in the face of global health challenges.

Investors should closely monitor the developments shared during this presentation, as ddPCR is noted for its versatility and technological superiority in diagnosing diseases, including cancer, and monitoring genetic therapies. With Bio-Rad reporting revenues of $2.6 billion in 2024, expectations around its growth trajectory remain high, especially with the expanding market for molecular diagnostics.

The webinar will also feature a Q&A session, giving participants the opportunity to probe further into Bio-Rad’s competitive advantages and market positioning. Anticipating a dialogue that covers industry trends and innovations can provide valuable insights for potential investment strategies.

In conclusion, participating in the webinar could offer substantial insights into Bio-Rad's innovative pipeline and market direction. Analysts and investors are encouraged to evaluate the forthcoming information critically; the commitment to technical excellence and customer-centric approaches may yield favorable long-term returns. Stay informed and ready to adapt to the evolving landscape in biotech investments.